Retrospective Study
Copyright ©The Author(s) 2024.
World J Clin Cases. Jul 16, 2024; 12(20): 4121-4129
Published online Jul 16, 2024. doi: 10.12998/wjcc.v12.i20.4121
Table 1 Primer sequences
Genes

Primer sequence
VEGFUpstream primer5’-AACACAGACTCGCGTTGCAA-3’
Downstream primer5’-ACCGCCTCGGCTTGTCA-3’
TGFβ1Upstream primer5’-GAGAAGAACYGCTGCGTGCGG-3’
Downstream primer5’-GCGTGTCCAGGCTCCAAATGT-3’
GAPDHUpstream primer5’-GATGACCTTGCCCACAGCCT-3’
Downstream primer5’-GGGTCATTGATGGCAACAATATC-3’
Table 2 Expression levels of vascular endothelial growth factor and transforming growth factor-β1
Group
Number of cases
VEGF
TGFβ1
AML group802.68 ± 0.160.33 ± 0.05
Healthy control group562.41 ± 0.120.45 ± 0.09
t10.6939.943
P value0.0000.000
Table 3 Correlations between clinical characteristics and vascular endothelial growth factor and transforming growth factor-β1 expression in patients with acute myeloid leukemia
Characteristic
Item
VEGF
χ2
P value
TGFβ1
χ2
P value
Low
High
Low
High
SexMale27300.5490.45929170.4170.518
Female13101915
Age (yr)< 6023290.2440.62221221.4270.232
≥ 6014142314
WBC (× 109/L)< 1014266.0540.01428118.6730.003
≥ 1025151625
Hb (g/L)< 8025165.0310.02516236.0040.014
≥ 8014252813
LDH (U/L)< 25013111.1640.2812192.5070.113
≥ 25023332624
Plt (%)< 8013287.1550.0071874.2460.039
≥ 8024152629
Table 4 Vascular endothelial growth factor and transforming growth factor-β1 expression in patients with acute myeloid leukemia with different treatment responses
Item
VEGF
TGFβ1
Healthy control (n = 56)2.41 ± 0.120.45 ± 0.09
Complete response (n = 36)2.42 ± 0.10a0.43 ± 0.11a
Partial response (n = 23)2.58 ± 0.13a0.37 ± 0.13a
No response (n = 21)2.67 ± 0.11a0.34 ± 0.09a
t35.92711.439
P value< 0.001< 0.001
Table 5 Factors influencing the prognosis of patients with acute myeloid leukemia
Item
OS
P value
DFS
P value
HR
95%CI
HR
95%CI
WBC0.3260.19-1.3510.0640.2410.091-0.8290.039
Plt0.5290.134-1.1310.0350.3910.109-0.8360.067
VEGF0.5090.206-1.6410.0190.4150.132-1.7290.034
TGFβ10.4310.221-1.4350.0260.3150.175-1.6350.027